Healthcare / BiotechnologyTaipei Exchange
$18.10
+0.25 (+1.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-31.7M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-18.8%
↓Gross Margin
69.1%
↑Debt/Equity
0.38
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-32.3%
FCF CAGR
—
FCF margin
-10.8%
FCF / Net income
0.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $232.7M · net income $-110.3M · FCF $-25.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $232.7M | $232.7M | $206.5M | $225.5M | $750.0M |
| Net Income | $-110.3M | $-110.3M | $-118.7M | $-166.3M | $221.3M |
| EBITDA | $-38.9M | $-38.9M | $-36.3M | $-143.7M | $344.2M |
| EPS | — | — | -2.07 | -2.89 | 3.77 |
| Gross Margin | 69.1% | 69.1% | 57.3% | 12.2% | 65.3% |
| Operating Margin | -37.3% | -37.3% | -65.8% | -92.2% | 32.0% |
| Net Margin | -47.4% | -47.4% | -57.5% | -73.7% | 29.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.38 | 0.38 | 0.38 | 0.31 | 0.38 |
| Current Ratio | 2.51 | 2.51 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-25.2M | $-25.2M | $-31.7M | $-60.6M | $307.2M |
| Returns | |||||
| ROE | -18.8% | -18.8% | -16.6% | -20.0% | 20.7% |
| Valuation | |||||
| P/E | — | — | — | — | 13.81 |
| EV/EBITDA | — | — | — | — | 7.97 |
| P/B | 1.77 | 1.77 | 2.23 | 2.75 | 2.89 |
| Growth & Yield | |||||
| Revenue Growth | 12.7% | 12.7% | -8.4% | -69.9% | — |
| EPS Growth | — | — | 28.4% | -176.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.07 → n/d
Residual
-18.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.